breast cancer
FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule
April 23, 2020Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma
Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …
Prostate Cancer becomes most commonly diagnosed cancer in England
January 28, 2020Manufacturing and Production Cancer, Cancer diagnoses, NHS England, breast cancer, prostate cancer
Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest …
China approves Roche cancer drug Kadcyla
January 22, 2020Business Services China, Roche, breast cancer, cancer treatment, oncology
China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the …
AI is more accurate than doctors at diagnosing breast cancer, study finds
January 2, 2020Business Services AI, AI Cancer, AI Trials, AI diagnoses, AI in clinical trials, Cancer, breast cancer
A recent study showed that Artificial Intelligence is more accurate than doctors in diagnosing breast cancer from mammograms. The research …
FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug
December 23, 2019Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer
The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …
AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals
December 20, 2019Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer
AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …
Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer
December 12, 2019Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
November 28, 2019Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma
Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …
Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma
NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …
NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer
October 3, 2019Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq
NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …
Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer
October 1, 2019Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq
Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …
Age affects efficacy of immunotherapy treatments in breast cancer patients
September 9, 2019Research and Development, Sales and Marketing Cancer, breast cancer, pharma
Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer
August 30, 2019Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq
Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …
NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer
August 7, 2019Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer
Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …
Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer
August 1, 2019Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
